NORD Explores the Economic Costs of Rare Disorders Dec 17, 2012 Together, there are nearly 7,000 orphan diseases that impact nearly 30 million Americans who NORD supports through education, research, and advocacy. Orphan Disease Market: Untapped Drug Development Opportunities Abound Dec 10, 2012 Orphan diseases used to be a lonely place in drug development. But with recent analyses showing high profitability potential, support from advocacy organizations, and new therapeutic approaches, companies are beginning to embrace rare diseases. Orphan Drugs or Personalized Medicine? Dec 05, 2012 With the continued development of drugs for specific diseases, disease populations and disease mechanisms, will the strategies applied to orphan drug development benefit the development of personalized medicines?
NORD Explores the Economic Costs of Rare Disorders Dec 17, 2012 Together, there are nearly 7,000 orphan diseases that impact nearly 30 million Americans who NORD supports through education, research, and advocacy.
Orphan Disease Market: Untapped Drug Development Opportunities Abound Dec 10, 2012 Orphan diseases used to be a lonely place in drug development. But with recent analyses showing high profitability potential, support from advocacy organizations, and new therapeutic approaches, companies are beginning to embrace rare diseases.
Orphan Drugs or Personalized Medicine? Dec 05, 2012 With the continued development of drugs for specific diseases, disease populations and disease mechanisms, will the strategies applied to orphan drug development benefit the development of personalized medicines?
